Myricetin bioactive effects: moving from preclinical evidence to potential clinical applications

作者：Yasaman Taheri, Hafiz Ansar Rasul Suleria, Natália Alves Martins, Oksana Sytar, Ahmet Beyatlı, Balakyz Kymyzgalievna Yeskaliyeva, Gulnaz Absattarovna Seitimova, Bahare Salehi, Prabhakar Semwal, Sakshi Painuli, Anuj Kumar, Elena Azzini, Miquel Martorell, William N. Setzer, Alfred Maroyi, Javad Sharifi‐Rad · 发表于：BMC Complementary Medicine and Therapies · 年份：2020 · DOI：10.1186/s12906-020-03033-z · 被引用次数：246 · 研究领域：Cholinesterase and Neurodegenerative Diseases、Medicinal Plants and Neuroprotection、Phytochemicals and Antioxidant Activities

Several flavonoids have been recognized as nutraceuticals, and myricetin is a good example. Myricetin is commonly found in plants and their antimicrobial and antioxidant activities is well demonstrated. One of its beneficial biological effects is the neuroprotective activity, showing preclinical activities on Alzheimer, Parkinson, and Huntington diseases, and even in amyotrophic lateral sclerosis. Also, myricetin has revealed other biological activities, among them as antidiabetic, anticancer, immunomodulatory, cardiovascular, analgesic and antihypertensive. However, few clinical trials have been performed using myricetin as nutraceutical. Thus, this review provides new insights on myricetin preclinical pharmacological activities, and role in selected clinical trials.